PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20650986-0	2011	Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1beta synthesis by human neutrophils.	Steroids	0-8	interleukin 1 receptor antagonist	Homo sapiens	45-78	
32631210-5	2020	We describe two cases where anakinra (human recombinant interleukin-1 receptor antagonist) was used as steroid-sparing therapy for life-threatening protracted paradoxical inflammation in HIV-associated TB.	Steroids	103-110	interleukin 1 receptor antagonist	Homo sapiens	56-89	
32398478-1	2020	Interleukin-1 (IL-1) receptor antagonist (anakinra) has been shown to be effective in steroid-dependent recurrent pericarditis resistant to nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine.	Steroids	86-93	interleukin 1 receptor antagonist	Homo sapiens	15-40	
20975573-0	2011	Interleukin 1 beta (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis.	Steroids	135-142	interleukin 1 receptor antagonist	Homo sapiens	57-63	
20975573-9	2011	CONCLUSIONS: IL-1 RN and IL-1B polymorphisms were associated with the genetic susceptibility to develop UC and might be associated with the presence of steroid-dependence in UC patients.	Steroids	152-159	interleukin 1 receptor antagonist	Homo sapiens	13-20	
20538031-9	2010	The higher doses of glucocorticosteroids needed in active LN could be due to steroid resistance and IL-1Ra polymorphism.	Steroids	32-39	interleukin 1 receptor antagonist	Homo sapiens	100-106	
15242697-3	2004	Steroids modulate some plasma cytokines (decreasing TNFalpha, IL-8, IL-6 and increasing IL-10), whereas ability to reduce plasma and urinary TNFsr-2 and IL-1ra and peri-operative renal injury is unknown.	Steroids	0-8	interleukin 1 receptor antagonist	Homo sapiens	153-159	
19162335-0	2009	The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy.	Steroids	162-169	interleukin 1 receptor antagonist	Homo sapiens	105-129	
19162335-3	2009	IL-1Ra and/or IL-1 RII increased in sera of all 10 investigated patients after the steroid treatment for relapse.	Steroids	83-90	interleukin 1 receptor antagonist	Homo sapiens	0-6	
35525835-12	2022	CONCLUSIONS: PMX-DHP combined with steroid pulse therapy might reduce GRO, IL-10, IL-1Ra, IL-5, IL-6, and MCP-1 levels in ARF, contributing to better oxygenation in the disorder.	Steroids	35-42	interleukin 1 receptor antagonist	Homo sapiens	82-88	
14519149-10	2003	In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.	Steroids	125-133	interleukin 1 receptor antagonist	Homo sapiens	82-88	
12568852-5	2003	INTERVENTION(S): Confluent stromal cell cultures treated with steroid hormones were stimulated with IL-1beta and attenuated by anti-IL-1beta antibody or IL-1 receptor antagonist.	Steroids	62-78	interleukin 1 receptor antagonist	Homo sapiens	153-177	
11073827-7	2000	However, IL-1Ra production was lower in steroid-resistant than in steroid-responsive rejection, and this difference was still observed 2 years after rejection.	Steroids	40-47	interleukin 1 receptor antagonist	Homo sapiens	9-15	
11073827-7	2000	However, IL-1Ra production was lower in steroid-resistant than in steroid-responsive rejection, and this difference was still observed 2 years after rejection.	Steroids	66-73	interleukin 1 receptor antagonist	Homo sapiens	9-15	
11073827-9	2000	Low IL-1Ra production is associated with steroid resistance of acute rejection and is due to a constitutional defect.	Steroids	41-48	interleukin 1 receptor antagonist	Homo sapiens	4-10	
8049450-4	1994	We performed an open-label, phase I/II trial to evaluate the safety and efficacy of IL-1Ra in 17 patients with steroid-resistant GVHD.	Steroids	111-118	interleukin 1 receptor antagonist	Homo sapiens	84-90